Latest results from the phase III IKEMA clinical trial evaluating the monoclonal antibody Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone (Kd) demonstrated a median progression free survival of 35.7 months (HR: 0.58; 95% CI: 25.8-44.0; n=179), compared to 19.2 months in patients treated with Kd alone (95% CI: 15.8-25.1; n=123), in patients with relapsed multiple myeloma.
The REZILIENT3 trial, a global phase III clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the first-line treatment of adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations, met its primary endpoint of progression-free survival at a planned interim analysis.
